key: cord-0950996-3wl8yosl authors: Carrington, Y. J.; Orlino, J.; Romero, A.; Gustin, J. R.; Rezaei, M.; Green, E.; Rose, S. L.; Aiyer, R. A.; Nasarabadi, S. title: COVID-19 Diagnostic Testing For All - Using Non-Dilutive Saliva Sample Collection, Stabilization and Ambient Transport Devices date: 2021-01-25 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2021.01.20.20243782 sha: 1854f48beda29a6eba645a5937ebd49ea03c75ad doc_id: 950996 cord_uid: 3wl8yosl Covid-19 testing is not accessible for millions during this pandemic despite our best efforts. Without greatly expanded testing of asymptomatic individuals, contact tracing and subsequent isolation of spreaders remains unobtainable as a means for control. In an effort to increase RT-PCR assay testing for the presence of the novel beta-coronavirus SARS-CoV-2 as well as improve sample collection safety, GenTegra LLC has introduced two products for saliva collection and viral RNA stabilization: GTR-STM (GenTegra Saliva Transport Medium) and GTR-STMdk (GenTegra Saliva Transport Medium Direct to PCR). Both products contain a proprietary formulation based on GenTegra's novel "Active Chemical ProtectionTM" (ACP) technology that gives non-dilutive, error-free saliva sample collection using RNA stabilization chemicals already dried in the collection tube. GTR-STM can be used for safer saliva-based sample collection at home (or at a test site). Following saliva collection, the sample-containing GTR-STM can be kept at ambient temperature during shipment to an authorized CLIA lab for analysis. SARS-CoV-2 viral RNA in GTR-STM is stable for over a month at ambient temperature, easily surviving the longest transit times from home to lab. GTR-STM enhances patient comfort, convenience, compliance and reduces infectious virus exposure to essential medical and lab professionals. Alternatively, the GTR-STMdk direct-into-PCR product can be used to improve lab throughput and reduce reagent costs for saliva sample collection and testing at any lab site with access to refrigeration. GTR-STMdk reduces lab process time by 25% and reagent costs by 30% compared to other approaches. Since GTR-STMdk retains SARS-CoV-2 viral RNA stability for three days at ambient temperature, it is optimized for lab test site rather than at home saliva collection. SARS-COV-2 viral RNA levels as low as 0.4 genome equivalents/uL are detected in saliva samples using GTR-STMdk. This increased sensitivity of SARS-CoV-2 detection can expand Covid-19 testing to include asymptomatic individuals using pooled saliva. The formal Limit of Detection (LoD) of SARS-CoV-2 in GTR-STM and GTR-STMdk in human saliva in individual and pooled samples will shortly be known. The global COVID-19 pandemic, caused by the novel beta-coronavirus SARS-CoV-2, continues to ravage countries, with the United States bearing the brunt of the attack, and other nations bracing for a second wave (1-3). Testing and contact screening are the primary tools necessary to prevent and contain the infection within communities (4) (5) (6) (7) (8) . Rapid strides have been made in advancing molecular and antigen-based testing, which measure viral RNA and surface protein respectively (9) (10) (11) (12) for the SARS-CoV-2. Significant progress has been achieved on three fronts, all of which play a significant role in improving patient comfort, patient convenience, and therefore, patient compliance. One major advancement is the shift away from complicated nasopharyngeal (NP) sampling to simpler saliva sampling. CDC guidance recommends nasopharyngeal (NP) swabs for collection of samples for SARS-CoV-2 RT-PCR testing (13) . NP sample collection can be uncomfortable, is not suitable for self-collection, and puts the health care professional at risk of infection (14, 15) . Some of the challenges for collection of NP sample include: (i) Difficulty in collection as the NP probe must be inserted deep into the nostril causing discomfort to the patient and often a gag/cough response. (ii) An element of risk for the trained healthcare professionals authorized to collect the NP sample (15, 16) . (iii) Shortages in availability of swabs and personal protective equipment for testing, a situation that led to significant under-testing of US populations at risk during the first few months of the pandemic (17, 18) . (iv) Requiring significant increases in the numbers of trained (currently insufficient) healthcare personnel to staff sample collection sites for testing to expand to mass screening. In contrast to NP swabs, saliva is a convenient, safe, and effective sample for SARS-CoV-2 testing, even for children (19) (20) (21) (22) . This makes it possible to have home saliva collection kits in which patients self-collect the saliva in a sampling tube, which is then mailed to a CLIAcertified laboratory for testing and analysis. Recently, the FDA has approved saliva as an alternate sample for COVID-19 testing (23). Saliva yields diagnostic test results comparable to NP swabs (22) . The ease of collection of saliva makes it ideal for the expansion of repeated testing programs in schools, workplaces, and for frequent travelers. Most saliva sampling and transport media products currently marketed require a two-step process for saliva collection. First, approximately 1mL of saliva must be expectorated (spat) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint into the sample tube. Second, an additional 1mL to 1.5mL of a sample-stabilizing liquid, supplied by the manufacturer, must be added to the saliva in the sampling tube (the rationale for this step is to preserve viral RNA integrity, and is discussed in detail in the next section). The second step above; addition of sample-stabilizing liquid, adds problems that may adversely affect the quality of downstream laboratory results. (i) Reliance on an untrained user to add the secondary liquid introduces the potential for error. If missed, the quality of the sample and therefore the integrity of the test result may be compromised due to viral RNA degradation in transport. (ii) More problematic is the fact that the initial viral load in 1mL of collected saliva will be diluted by the additional stabilizing liquid, reducing the detectability of samples with low viral loads, increasing the potential to yield false negative results. (iii) The dilution problem will be particularly acute when mass screenings for SARS-CoV-2 are extended to asymptomatic individuals in schools, workplaces, and to travelers, many of whom may have low or very low levels of virus in saliva. Dilution of these samples by adding a secondary liquid can cause low positive samples to be missed. (iv) The issue of false negative results due to sample dilutive media will also be a severe problem with the adoption of pooled testing, where multiple samples may be combined with a low level positive in a pool, thereby impacting the Limit of Detection (LoD) of the assay. Unlike a DNA sample (such as from a human genome test), which is very stable and maintains its molecular integrity under a variety of harsh conditions, RNA in saliva, which is RNAse-rich, is notoriously unstable and easily degraded. This accounts for the wide variation in test results reported in terms of high false negatives and LoD's. To address this problem, assay protocols typically incorporate two additional steps before starting the PCR reaction. (i) Immediately after sample collection viral RNA stabilization media is added to ensure RNA integrity in the test samples. (ii) An aliquot of the diluted specimen is withdrawn, and the RNA is then subjected to an amplification process to ensure that sufficient quantities are available to serve as a PCR reaction template. These additional sample treatment steps automatically bring with them more possibilities for error, potentially impacting the quality and accuracy of the test result. The ultimate solution is to find a way to eliminate these steps, by directly adding the undiluted and non-pre-treated saliva to the PCR reaction. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Two devices that address the limitations of saliva sample collection described above are GTR-STM and GTR-STMdk. They were developed by GenTegra LLC, a Pleasanton, Californiabased company focused on developing products for ambient temperature stabilization and storage of RNA, DNA, proteins, and other biomolecules. The company's Active Chemical Protection™ (ACP) technology incorporates a proprietary combination of small molecule inhibitors, cytotoxins, antioxidants, metal chelators, and anti-microbials to provide total protection for viral RNA at ambient temperatures. Proprietary ACP chemistry reduces saliva viscosity, inactivates contaminating RNases, and comprises ingredients that inactivate viruses and bacteria. The formulation renders the sample safe for transportation and testing. Furthermore, ACP is guanidinium-free, which makes it compatible with lab automation and selfsterilizing PCR instrumentation. Both the GenTegra sample collection devices incorporate a non-dilutive dried media formulation at the bottom of the collection tube that eliminates sample dilution when oral fluid (saliva) is added by simply expectorating into the tube. The ionic and non-ionic denaturants in GTR-STM and the enzymes in GTR-STMdk inactivate the virus by disrupting the lipid envelope of the virus, rendering the saliva safe for transportation and testing. In order to further sterilize the saliva samples, the saliva in both GTR-STM and GTR-STMdk can be heated at 95C for 15 minutes while still maintaining the integrity of the viral RNA for downstream RT-PCR analysis. Unlike EUA-approved home saliva kits available on the market, no additional liquid medium need be added to the saliva sample collected. The dried saliva transport medium in GTR-STM and GTR-STMdk dissolves upon contact with the saliva, thereby stabilizing the viral RNA. GTR-STM and GTR-STMdk makes a more concentrated and more stable RNA sample available for PCR, likely improving the assay LoD. The distinct features and benefits of the two products are described below. • Optimized for home-based saliva sample collection • For use with legacy high-throughput RT-PCR assay systems, which incorporate an RNA extraction and pre-amplification step All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. • Retains SARS-CoV-2 viral RNA stability with minimal RNA degradation for up to three days at ambient temperature (the time typically required for saliva sample collection and Direct into PCR testing in a lab setting) and up to nine days at 4°C. • Improves workflow due to: o Direct addition of saliva sample to RT-PCR process due to specially modified dry formulation o Eliminates need for sample pre-extraction step prior to RT-PCR assay, saving 25% in lab processing time o Can be used with sample volumes as low as 3.75uL and 30% less quantity of RT-PCR reagents • Significant reduction in turnaround times for reporting assay results • Significant reduction in testing cost by bypassing costs associated with sample extraction The workflow using GTR-STM is summarized in Figure 1 , left side. After saliva samples are received either from test-site or home collection, they are kept at ambient temperature until All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint ready to process. They are then disinfected by heating at 95°C for 15 minutes in order to further protect lab personnel. The next step is a crucial prerequisite for successful RT-PCR. Aliquots (100 to 400 uL) of the sample are subjected to extraction using appropriate commercially available reagents (process time = nearly one hour). Then, 3.75 to 5uL of the extracted RNA sample is amplified in a total reaction volume of 10uL to 15uL of RT-PCR mix (process time = nearly one hour) followed by analysis. The entire lab test process including and up to recording of results in the system takes about four hours. (Note: the time from lab workflow process to actual delivery of assay results to patients varies from lab to lab and may take more than 24 hours after sample receipt.) The workflow using GTR-STMdk is summarized in Figure 1 , right side. Here, following saliva collection at the lab, the samples are kept at ambient temperature for 60 minutes to enable complete dissolution of the dried chemicals and activation of pre-dried Proteinase K (process time = nearly one hour). The samples are then heated for 15 minutes at 95C (process time = nearly 15 minutes). This step will kill any residual Proteinase K that could potentially interfere with Taq polymerase during RT-PCR and simultaneously disinfect the samples to ensure lab personnel safety. The samples are then cooled at 4C for five minutes before adding directly into the RT-PCR reaction system for assay and analysis (process time = nearly one hour). Since there is NO extraction and pre-amplification step, the entire process up to recording of results in the system takes about three hours. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint CDC guidelines suggest using N1 and N2 primers for amplification in the RT-PCR assay for SARS-CoV-2. We ran a comparative analysis of N1 and N2 primer data using SARS-CoV-2-RNA spiked saliva and established by ANCOVA that the data obtained from either primer (N1 or N2) were statistically equivalent (Supplement S1). Therefore, due to cost and time considerations, all studies reported in this paper (except Figure 6 ) were performed using only the N1 primer from CDC. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint Experimental Sample: A contrived GTR-STM sample (n=9) was prepared by spiking 1mL of saliva with 2 genome equivalents/uL of -gamma-irradiated SARS-CoV-2 virus. Saliva has a high concentration of RNase (24) . When saliva samples containing SARS-CoV-2 are collected at home and shipped to the remote testing site, there is the likelihood that during transport at ambient temperatures, the viral RNA could be degraded due to exposure to raw saliva. However, the presence of proprietary ACP chemistry in GTR-STM protects and stabilizes the SARS-CoV-2 viral RNA (Figure 3 ). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figure 2 , blue bars) compared to -80C control (Figure 2, maroon bars) The stability studies were further extended using heat-inactivated whole SARS-CoV-2 virus (sourced from BEI resources) spiked into saliva in GTR-STM. When spiked into saliva with GTR-STM, the heat-inactivated SARS-CoV-2 virus was stable for up to 36 days at 25C, and up to seven days at 56C, prior to RNA extraction and RT-qPCR analysis (Figures 4 and 5) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Experimental Samples: 1 mL aliquots of saliva contrived with SARS-CoV-2 at 500 genome equivalents/uL (BEI Resources) were placed into either GTR-STM devices or non-GTR-STM ("Saliva") tubes and stored at ambient (25C) for up to 36 days. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. Surprisingly, under non-GTR-STM ("Saliva") storage, even the -80C stored samples showed inconsistent retention of CT levels below "Pass/Fail." It is likely that in these frozen samples, SARS-CoV-2 viral RNA degradation occurred even during the very short five-minute thaw at 4C prior to RT-PCR. Figure 5 shows an accelerated stability study by storing samples at an elevated temperature of 56C. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Heat inactivated SARS-CoV-2 virus spiked saliva in GTR-STM retained its stability for up to seven days in GTR-STM. The data show indistinguishable CT values between samples stored All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint at 56C and -80C, with all CT levels below the "Pass/Fail" criterion. This 56C stability for seven days implies equivalent temperature stability at ambient (25C) for stored samples of approximately 60 days, based on the Arrhenius equation for temperature dependence of reaction rates. Regression analysis performed (t-statistic test, P<0.05, R-squared value 0.625) based on the seven days data suggests that saliva containing SARS-CoV-2 virus collected in GTR-STM potentially be extrapolated to show stability at ambient temperature more than 214 days (Supplemental Data, S3). The stability data in Figures 4 and 5 demonstrate the utility of GTR-STM as a saliva sample collection device in a home setting, allowing for sufficient time from collection, shipping/transportation, and RT-PCR assay under highly variable temperature conditions. Even though GTR-STM media contains components known to inactivate SARS-CoV-2, to ensure an added measure of safety of lab personnel, incoming sample specimens must be pre-heated at 95C for 15-30 minutes to inactivate any residual live SARS-Cov-2 that may be present (25, 26) . Figure 6 shows that SARS-CoV-2 viral-spiked saliva samples in GTR-STM can be preheated at 95C for up to 30 minutes prior to RT-PCR without adversely affecting assay sensitivity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint Experimental Samples: Saliva sample was contrived with 2,000 and 2.0 geq/uL gammairradiated SARS-CoV-2 virus per uL. 1mL each of contrived samples were added to GTR-STM, heated at 95C for up to 30 minutes. Sample Extraction: RNA was extracted from 50uL of sample with QIAamp viral RNA kit and eluted in 50uL of elution buffer. Quantification: 5uL of RNA was quantified by CDC's N1, N2 and Rnase P primer sets. The data in Figure 6 showed that pre-heating of viral samples for 15 minutes or up to 30 minutes at 95C gave CT values that were consistent with ambient samples using CDC's N1, N2 or Rnase P primers for quantification. The N2 primer yielded higher CT values than N1. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Perhaps the N1 primer binds to a more stable section of the SARS-CoV-2 viral RNA and therefore could be better suited to obtain greater sensitivity in RT-PCR testing for COVID-19. Figures 2 -6 ) clearly establish that GTR-STM is a valuable home saliva sample collection device since it (i) retains SARS-CoV-2 activity for 36 days at ambient temperature following sample collection and transportation to a testing lab, (ii) retains SARS-CoV-2 activity for up to seven days at 56C, which translates to approximately 60 days at ambient temperature, (iii) can withstand heating conditions up to 56C that may be encountered perhaps unexpectedly at transit points during shipping, and (iv) maintains viral RNA stability during disinfection by heating for up to 30 minutes at 95C. While the GTR-STM device solves the problem of dilution described earlier, diagnosticians are still left with the additional complication of the required extraction of viral RNA prior to PCR. Eliminating this step would significantly lower reagent costs per test, while also improving assay turnaround times, particularly when processing thousands of test samples. This second complication has also been resolved successfully with an improved device, GTR-STMdk. Based on feedback from CLIA-lab partners, the "direct-into-PCR" product GTR-STMdk, eliminates the crucial 60 minute-pre-extraction and RNA amplification step. This is a significant advance as it saves up to 25% of workflow process time and reduces the added costs of non-PCR reagents. The key difference between GTR-STM and GTR-STMdk is the addition of Proteinase K pre-dried along with the RNA stabilization chemistry. Proteinase K degrades the viral coat, releasing the RNA and therefore eliminating the need of pre-extraction for RNA amplification. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 500uL of saliva contrived with gamma-irradiated SARS-CoV-2 virus, 2 geq /uL, was added to GTR-STMdk device. Six replicates each with; (i) 5uL of sample to 10uL of TaqPath RT-PCR master mix, (ii) 3.75uL of sample to 10uL of master mix, (iii) 5uL of sample to 15uL of master mix (ThermoFisher volume). Experimental Samples were added directly into the RT-PCR assay after first heating for five minutes at 56C, followed by 15 minutes at 95C, and then cooling for 5 minutes at 4C ("Direct into PCR" in Figure 8 ). Control Samples were extracted with QIAamp viral RNA kit from 100uL of saliva sample. The extracted RNA was eluted in 100uL of Elution Buffer (CT, STMdk Extracted), then subjected to RT-PCR ('Matched Extracted RNA" in Figure 7) Quantification: 3.75uL to 5uL of RNA was quantified with CDC's SARS-CoV-2 RT-qPCR assay for N1 primer. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint The results show that similar CT values were obtained using a total RT-PCR volume of 13.75uL comprising 3.75uL test sample and 10uL of reagent master mix versus 20uL comprising 5uL test sample versus 15uL reagent master mix. Thus, potential savings in reagent costs of up to 30% could be realized using GTR-STMdk. The practical utility of the GTR-STMdk device was further explored to account for variable volumes of saliva samples collected on site. COVID-19 patients may experience difficulties in generating sufficient saliva volumes due to their weakened condition. Figure 8 shows RT-PCR data in which contrived saliva sample volumes of 50uL, 100uL, 500uL and 1,000uL were placed inside GTR-STMdk devices. Various volumes, 50uL, 100uL, 500uL and 1,000uL of Contrived Saliva at 0.4 geq/uL and 2.0 geq/uL of gamma-irradiated SARS-CoV-2 (BEI Resources) added to STMdk devices. Experimental Samples were heated for 5 minutes at 56C, then heated for 5 minutes at 95C, cooled for 5 minutes at 4C, then subjected to direct RT-PCR. Control Samples were extracted with QIAamp viral RNA kit from 100uL of saliva sample. The extracted RNA was eluted in 100uL of Elution Buffer (CT, STMdk Extracted). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint Quantification: 5uL of RNA was quantified with CDC's SARS-CoV-2 RT-qPCR assay for N1 primer. At both the low and high doses of SARS-CoV-2, samples at all saliva volumes tested gave CT values below the "Pass/Fail" criterion. Therefore, the GTR-STMdk device would be suitable for use with saliva sample volumes as low as 50uL and as high as 1mL. Also, compared to the samples in Figure 7 , the direct to PCR samples in Figure 8 were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. CoV-2 viral RNA for up to nine days at 4C (data not shown). Therefore, the GTR-STMdk device is ideally suited for sample collection at testing sites, such as clinical labs, where the device can be quickly refrigerated following saliva sample collection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Many countries, including US, are still in the grips of the COVID-19 pandemic while other countries are experiencing a resurgence or a potential second wave. Mass screening for the presence of SARS-CoV-2 in the general population has become an imperative. GTR-STM and GTR-STMdk provide essential technological advances in COVID-19 testing, by enhancing the ease of sample collection, increasing assay sensitivity, improving safety and facilitating lab workflow while enabling lower costs and faster turnaround times. Saliva sampling is a safer, more convenient and practical alternative to nasopharyngeal swabs. GenTegra has been on the forefront of developing dried-media sample collection devices for a variety of testing applications, and this technology has been logically extended to develop two non-dilutive saliva collection products, GenTegra GTR-STM and GTR-STMdk. GenTegra's proprietary Active Chemical Protection chemistry is particularly applicable to SARs-CoV-2 PCR assays where prevention of RNA degradation and preservation of stability during transport from sample collection to lab test sites is essential to ensuring high test accuracy and sensitivity. GTR-STM, while a simple device, has the following attributes: (i) direct collection of saliva by expectoration into a tube containing dried stabilizers to avoid sample dilution, (ii) use of stabilizers that are generally known to inactivate infectious virus, and (iii) SARS-CoV-2 stability for up to 60 days at ambient temperature. At the test site, the viral RNA in the sample would need to be extracted and amplified before PCR analysis. Due to its ability to retain viral RNA stability for several weeks at ambient temperature, GTR-STM would be ideally suited for home-based sample collection after which the sample containing devices may be shipped and transported worldwide at temperatures up to 56C to authorized CLIA labs.. GTR-STMdk incorporates Proteinase K into the saliva sample collection device itself, eliminating the Proteinase K addition step at the testing site, which reduces potential avenues for error. In addition, the sample can be directly subjected to RT-PCR without the need for RNA pre-amplification. The benefit of NOT requiring RNA extraction and amplification at the test site provides a substantial improvement to throughput by reducing test turnaround times. In SARS-CoV-2 spiked saliva samples collected in GTR-STMdk, virus levels down to 0.4 geq/uL can be detected using as little as 3.75uL of sample volume and 30% less quantity of expensive PCR assay reagents. The device is also effective with saliva collection volumes as low as 0.05 mL, minimizing difficulty for patients struggling to provide a usable sample when under stress. GTR-STMdk is ideally suited for sample collection at locations proximal to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A comparison of the characteristics and utility of the two devices is given in Table 1 . GTR-STM GTR-STMdk Table 2 provides a comparison of the attributes of GTR-STM and GTR-STMdk to other saliva collection products currently marketed. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint Table 2 : GTR-STM and GTR-STMdk comparative saliva collection devices. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01. 20.20243782 doi: medRxiv preprint In this report, the saliva used was from a commercially available source. Studies are in progress in GenTegra labs as well in collaboration with CLIA lab partners to confirm these data using individual human saliva samples. We have provided a conservative estimate for assay sensitivity, pending a more formal determination of test Limit of Detection (LoD) for samples collected in GTR-STM and GTR-STMdk. The switch to dry chemical saliva sample collection devices GTR-STM and GTR-STMdk, can achieve significant improvements in SARS-CoV-2 RT-PCR testing throughput efficiencies. Saliva sampling with GTR devices also greatly enhances patient convenience, safety, reduces testing costs and reporting times for test results. The enhancement to accuracy, sensitivity and PCR assay turnaround times using GTR devices can greatly expand the number of asymptomatic individuals that can be tested on a regular basis while facilitating testing on pooled samples. The numerous sample testing advances provided by GTR devices are essential to support COVID-19 testing for all, with the ultimate critical goal to better control the ongoing pandemic until a safe and efficacious viral vaccine and therapies becomes widely available. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status Global coronavirus disease 2019: What has daily cumulative index taught us? Efficacy of contact tracing for the containment of the 2019 novel coronavirus (COVID-19) Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study Contact Tracing and Asymptomatic Transmission of Novel Coronavirus Disease (COVID-19): A Modelling Study Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection COVID-19: molecular diagnostics overview Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. medRxiv Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2 Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease Saliva-based PCR tests for SARS-CoV-2 detection Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy The Appropriate Use of Testing for COVID-19 Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage Facial protection for healthcare workers during pandemics: a scoping review No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Self-Collected Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2 New COVID-19 saliva-based test: How good is it compared with the current nasopharyngeal or throat swab test? Saliva is a promising alternative specimen for the detection of SARS-CoV-2 in children and adults. medRxiv A hybrid chimeric system for versatile and ultrasensitive RNase detection Inactivation of the 170 coronavirus that induces severe acute respiratory syndrome, SARS-CoV Using heat to kill SARS-CoV-2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 25, 2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Study setup for each set of experiments is given in the respective legend below each Figure Two different heating methods were tested with contrived saliva in GTR-STMdk. First, samples were heated at 56C for 5 minutes, before being heated at 95C for 5 minutes. The second method tested was heating at 95C for 15 minutes to deactivate the Proteinase K in the solution. The second method was sufficient in deactivating the Proteinase K before RT-qPCR and provided similar results to the first method, so the 56C for 5 minutes step was removed. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Criteria for determination of SARS-CoV-2 positivity in RT-PCR Assay: Based on FDA guidance, samples were considered positive if the CT value was less than the "Pass/Fail" criterion of Mean CT + 3CT, and negative if above the "Pass/Fail" criterion.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.20.20243782 doi: medRxiv preprint